Protocol Ledger

NCT03567889 · Phase III · RECRUITING

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Interventional Phase III clinical trial protocol NCT03567889 sponsored by Philogen S.p.A in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-20 Enrollment: 186 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03567889
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)186 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03567889
Protocol FieldVerified Registry Value
NCT IdentifierNCT03567889
Consolidated Lead SponsorPhilogen S.p.A
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment186 participants (ESTIMATED)
Registered Start Date2018-09-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI